Cytokinetics, Incorporated (CYTK) stock analysis
In our weekly check, Cytokinetics, Incorporated is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 8 pass, warnings: 2, red flags: 12.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as CYTK.
What our checks show for CYTK
Red flags
- The company has net debt but no positive operating earnings (EBITDA) to service it from, and equity is negative: on the balance sheet, liabilities exceed assets.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The net margin fell by 381 points over 5 years, to -687%: the company keeps less of each sale as profit.
- Weak EPS forecast
- Weak EPS growth
- The company is losing money: the net margin is -687%.
- Free cash flow is negative (-472% of revenue): the business spends more cash than it brings in.
- The stock has fallen as much as 94% from a peak. Would you have held through that?
- Recovering from its deepest fall took about 7.7 years.
- The share count grew by 24.3% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The price swings a lot: 43.6% annual volatility. Expect large ups and downs.
Strengths
- The gross margin is 91% and has risen by 218 points: pricing power is holding.
- Analysts expect revenue to grow about 154% a year over the next years.
- Analysts expect the net margin to improve by 659 points from today's -687%.
- Beta 0.36: the stock usually moves less than the market.
Similar companies
ABVX · RYTM · AXSM · TWST · PTGX · ORKA
Questions
What grade does Cytokinetics, Incorporated (CYTK) have?
In our weekly check, Cytokinetics, Incorporated is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 8 pass, warnings: 2, red flags: 12. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of CYTK stock?
This week's biggest flags for Cytokinetics, Incorporated: High debt, Weak interest cover, Margins falling. In total 14 of 22 checks show a warning or a red flag.
What does Cytokinetics, Incorporated do?
Cytokinetics, Incorporated is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as CYTK.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis